Age-related macular degeneration (AMD) is a leading cause of blindness. The EMA has issued a Letter of Support to Innovative Medicines Initiative project MACUSTAR for its work on new measures to assess AMD in clinical trials.
A White House body wants more research into lab safety measures, while the Commission has asked member states to review their rules. But action has so far been limited
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.